MARKET

ZVSA

ZVSA

ZyVersa Therapeutics Inc
NASDAQ
0.5272
-0.0440
-7.70%
After Hours: 0.5101 -0.0171 -3.24% 19:57 05/09 EDT
OPEN
0.5600
PREV CLOSE
0.5712
HIGH
0.5700
LOW
0.4728
VOLUME
868.50K
TURNOVER
--
52 WEEK HIGH
6.69
52 WEEK LOW
0.4728
MARKET CAP
1.91M
P/E (TTM)
-0.0622
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 4d ago
ZyVersa Therapeutics announces developments on inflammasome inhibitors
TipRanks · 4d ago
ZyVersa Announces Release Of Inflammasome Inhibitors In Combination with GLP-1 Agonists To Address Unmet Medical Needs Of People Living with Obesity
Benzinga · 4d ago
ZYVERSA UNVEILS GROUNDBREAKING POTENTIAL OF INFLAMMASOME INHIBITORS IN COMBINATION WITH GLP-1 AGONISTS TO ADDRESS UNMET MEDICAL NEEDS OF PEOPLE LIVING WITH OBESITY; PROVIDES R&D UPDATE
Reuters · 4d ago
Weekly Report: what happened at ZVSA last week (0428-0502)?
Weekly Report · 6d ago
ZyVersa Therapeutics Publishes Data Supporting Potential Of Its Inflammasome ASC Inhibitor IC 100
NASDAQ · 04/29 16:56
ZyVersa Therapeutics announces publication of data on inflammasome inhibition
TipRanks · 04/29 12:12
More
About ZVSA
More
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Recently
Symbol
Price
%Change

Webull offers Zyversa Therapeutics Inc stock information, including NASDAQ: ZVSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVSA stock methods without spending real money on the virtual paper trading platform.